The frontier of health: Exploring therapeutic potentials of the microbiome

IF 2.4 Q3 NUTRITION & DIETETICS PharmaNutrition Pub Date : 2025-02-06 DOI:10.1016/j.phanu.2025.100435
Mohammad Abavisani , Sobhan Karbas Foroushan , Prashant Kesharwani , Amirhossein Sahebkar
{"title":"The frontier of health: Exploring therapeutic potentials of the microbiome","authors":"Mohammad Abavisani ,&nbsp;Sobhan Karbas Foroushan ,&nbsp;Prashant Kesharwani ,&nbsp;Amirhossein Sahebkar","doi":"10.1016/j.phanu.2025.100435","DOIUrl":null,"url":null,"abstract":"<div><div>The human body harbors a vast and complex community of microorganisms, primarily bacteria residing in the gut. This gut microbiome significantly impacts our health, influencing digestion, nutrient absorption, immune function, and potentially even mental well-being. An imbalance in this microbial community, termed dysbiosis, has been linked to various human diseases. This realization has opened doors to exciting possibilities in healthcare: microbiome-based therapies that aim to restore gut balance and modulate the immune response. Fecal microbiota transplantation (FMT), involving transplanting stool from a healthy donor, and live probiotic microorganisms are two common microbiome-based therapies. Apart from consuming high-fiber foods such as the Mediterranean diet, dietary approaches for altering the microbiome include adding prebiotics that encourage the development of beneficial microorganisms. However, microbiome-based therapies are not a one-size-fits-all solution. Individual variability in gut microbiome composition across people can affect effectiveness of these therapies. Establishing clear regulations and safety protocols, addressing ethical concerns through open communication, informed consent, and responsible marketing practices, are essential for the responsible use of these therapies. Our study will examine microbiome-based therapy from its premise and mechanism to its current state of development. Additionally, development challenges and potential solutions to inspire further investigations will be discussed.</div></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":"31 ","pages":"Article 100435"},"PeriodicalIF":2.4000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmaNutrition","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213434425000076","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0

Abstract

The human body harbors a vast and complex community of microorganisms, primarily bacteria residing in the gut. This gut microbiome significantly impacts our health, influencing digestion, nutrient absorption, immune function, and potentially even mental well-being. An imbalance in this microbial community, termed dysbiosis, has been linked to various human diseases. This realization has opened doors to exciting possibilities in healthcare: microbiome-based therapies that aim to restore gut balance and modulate the immune response. Fecal microbiota transplantation (FMT), involving transplanting stool from a healthy donor, and live probiotic microorganisms are two common microbiome-based therapies. Apart from consuming high-fiber foods such as the Mediterranean diet, dietary approaches for altering the microbiome include adding prebiotics that encourage the development of beneficial microorganisms. However, microbiome-based therapies are not a one-size-fits-all solution. Individual variability in gut microbiome composition across people can affect effectiveness of these therapies. Establishing clear regulations and safety protocols, addressing ethical concerns through open communication, informed consent, and responsible marketing practices, are essential for the responsible use of these therapies. Our study will examine microbiome-based therapy from its premise and mechanism to its current state of development. Additionally, development challenges and potential solutions to inspire further investigations will be discussed.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
PharmaNutrition
PharmaNutrition Agricultural and Biological Sciences-Food Science
CiteScore
5.70
自引率
3.10%
发文量
33
审稿时长
12 days
期刊最新文献
Aloe vera and its byproducts as sources of valuable bioactive compounds: Extraction, biological activities, and applications in various food industries Free acid β-hydroxybutyrate supplementation does not ameliorate dextran sodium sulfate-induced colitis similar to ketogenic diet in male mice The frontier of health: Exploring therapeutic potentials of the microbiome Moringa oleifera leaf powder enhances glycemic control in sahrawi women with type 2 diabetes: Findings from a 3-month unblinded randomized controlled trial Mechanism of Epigallocatechin-3-gallate in the prevention and treatment of irritable bowel syndrome: A network pharmacology and gene expression omnibus chip data-based study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1